America’s Opioid Epidemic: a Comprehensive Review and Look into the Rising Crisis
Purpose of Review In the USA, there has been a sharp increase in heroin, prescription opiate, and illicitly manufactured fentanyl abuse with overdoses tripling since the 1990s. Several states have been deemed as “high-burden” abuse states where there is a greater proportion of synthetic opiate use. During the same period that prescription limitations were initially implemented throughout the country, the fentanyl epidemic started nationwide. Recent Findings In the setting of data demonstrating an almost fourfold increase in overdose deaths from 1999 to 2008, states began restricting access to Food and Drug Agency (FDA) approved opioid medications. Another factor further exacerbating the opioid crises is that the cost of all formulations of naloxone has increased significantly over the past several years. Summary In order to combat the opioid epidemic, stricter prescribing practices and prescription-monitoring programs have been instituted. Also, improvements in abuse-deterrent strategies for all opioid preparations can play an important role by increasing the safety of these medications and is a major focus of the FDA..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2018 |
---|---|
Erschienen: |
2018 |
Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
---|---|
Enthalten in: |
Current Review of Pain - 22(2018), 5 vom: 04. Apr. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ostling, Peter S. [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Themen: |
Fentanyl |
---|
doi: |
10.1007/s11916-018-0685-5 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR023012862 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR023012862 | ||
003 | DE-627 | ||
005 | 20230520013014.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201006s2018 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s11916-018-0685-5 |2 doi | |
035 | |a (DE-627)SPR023012862 | ||
035 | |a (SPR)s11916-018-0685-5-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Ostling, Peter S. |e verfasserin |4 aut | |
245 | 1 | 0 | |a America’s Opioid Epidemic: a Comprehensive Review and Look into the Rising Crisis |
264 | 1 | |c 2018 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Purpose of Review In the USA, there has been a sharp increase in heroin, prescription opiate, and illicitly manufactured fentanyl abuse with overdoses tripling since the 1990s. Several states have been deemed as “high-burden” abuse states where there is a greater proportion of synthetic opiate use. During the same period that prescription limitations were initially implemented throughout the country, the fentanyl epidemic started nationwide. Recent Findings In the setting of data demonstrating an almost fourfold increase in overdose deaths from 1999 to 2008, states began restricting access to Food and Drug Agency (FDA) approved opioid medications. Another factor further exacerbating the opioid crises is that the cost of all formulations of naloxone has increased significantly over the past several years. Summary In order to combat the opioid epidemic, stricter prescribing practices and prescription-monitoring programs have been instituted. Also, improvements in abuse-deterrent strategies for all opioid preparations can play an important role by increasing the safety of these medications and is a major focus of the FDA. | ||
650 | 4 | |a Fentanyl |7 (dpeaa)DE-He213 | |
650 | 4 | |a Heroin |7 (dpeaa)DE-He213 | |
650 | 4 | |a Opioid abuse |7 (dpeaa)DE-He213 | |
650 | 4 | |a Opioid addiction |7 (dpeaa)DE-He213 | |
650 | 4 | |a Opioid epidemic |7 (dpeaa)DE-He213 | |
650 | 4 | |a Opioid overdose |7 (dpeaa)DE-He213 | |
700 | 1 | |a Davidson, Kelly S. |e verfasserin |4 aut | |
700 | 1 | |a Anyama, Best O. |e verfasserin |4 aut | |
700 | 1 | |a Helander, Erik M. |e verfasserin |4 aut | |
700 | 1 | |a Wyche, Melville Q. |e verfasserin |4 aut | |
700 | 1 | |a Kaye, Alan D. |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Current Review of Pain |d Current Medicine Group, 1998 |g 22(2018), 5 vom: 04. Apr. |w (DE-627)SPR023001666 |7 nnns |
773 | 1 | 8 | |g volume:22 |g year:2018 |g number:5 |g day:04 |g month:04 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11916-018-0685-5 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |d 22 |j 2018 |e 5 |b 04 |c 04 |